In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FerroKin BioSciences, Inc.

http://www.ferrokin.com/

Latest From FerroKin BioSciences, Inc.

Imago Raises $80m Series C To Take Bomedemstat Into Phase III

The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.

Financing Business Strategies

Postmarket Surveillance Reform Board Gets Injection Of Device Industry Experience

The appointments of three device industry veterans to the Brookings-administered, and partially FDA-funded, Planning Board is intended to expand the range of input in the next phase of development of a new National Medical Device Surveillance System.

Medical Device Regulation

Medtech Execs On The Move, August 2015

Recent executive-level company changes and promotions in the medical device and diagnostics industries.

Medical Device

InPress Technologies Inc.

There are approximately 140,000 fatalities a year from postpartum hemorrhage, mostly in low- to middle-income countries, and thus a pressing need to reduce mortality. A new low-pressure suction device from InPress Technologies Inc. that is inserted into the uterus following childbirth has the potential to initiate blood control within two minutes and reach full restoration of uterine tone in just over two hours.

Medical Device
See All

Company Information

UsernamePublicRestriction

Register